When was Bolt Biotherapeutics founded?

Bolt Biotherapeutics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Bolt Biotherapeutics located?

Bolt Biotherapeutics is headquartered in Redwood City, United States. It is registered at Redwood City (United States).

How many employees does Bolt Biotherapeutics have?

As of Mar 31, 2026, the latest employee count at Bolt Biotherapeutics is 54.

Is Bolt Biotherapeutics a funded company?

Bolt Biotherapeutics is a funded company, having raised a total of $177M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 06, 2015.

When was the latest funding round of Bolt Biotherapeutics?

Bolt Biotherapeutics' latest funding was a $***** Post IPO round on Jun 07, 2021, with participation from 0 investor.

What is the annual revenue of Bolt Biotherapeutics?

Annual revenue of Bolt Biotherapeutics is between $1M and $10M as on Dec 31, 2025

Where does Bolt Biotherapeutics rank among its competitors?

Bolt Biotherapeutics ranks 32nd amongst 559 active competitors, of which 230 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Bolt Biotherapeutics?

Bolt Biotherapeutics' top competitors include Immuneel, Abcellera Biologics and Agios Pharmaceuticals. Among them, Immuneel secured the most recent funding round in June, 2026.

Bolt Biotherapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of T-cell therapies for the treatment of cancer. The proprietary platform Boltbody immune-stimulating antibody conjugate has an approach to design anti-tumor therapeutics. The product pipeline includes BDC-3042 which is Dectin-2 agonist antibody that works by repolarizing immune cells from tumor-supportive to tumor-destructive

Website: boltbio.com
Email ID: *****@boltbio.com
Phone Number: +1 **********
Registered Address: Redwood City (United States)

Key Metrics

Founded Year

2015

Location

Redwood City, United States

Stage

Public

Total Funding

$177M in 7 rounds

Latest Funding Round

Post IPO, Jun 07, 2021, $*****

Investors

Sofinnova Investments & 8 more

Ranked

32^nd among 559 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

54 as on Mar 31, 2026

Similar Companies

Immuneel & 681 more

Exit Details

Public

View Bolt Biotherapeutics' full profile

Bolt Biotherapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Bolt Biotherapeutics, Inc. CIN: 001-39988 , United States, Active	Jan 21, 2015	-	94 (As on Dec 31, 2022)	-
Bolt Biotherapeutics, Inc. CIN: 1641281 , United States, Active	Jan 21, 2015	$1M - $10M (As on Dec 31, 2025)	-	-

Bolt Biotherapeutics got listed on Feb 05, 2021.

Click here to take a look at Bolt Biotherapeutics's IPO in detail

Bolt Biotherapeutics has raised a total funding of $177M over 7 rounds. Its first funding round was on May 06, 2015. Bolt Biotherapeutics has 9 institutional investors.

Here is the list of recent funding rounds of Bolt Biotherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 07, 2021	7278859	Post IPO	8094612	1472681	9293945	5484342
Jul 01, 2020	4802812	Series C	2735684	7618562	5043839	RA Capital Management & 6 more
Feb 05, 2019	4495402	Series B	2254895	8234588	Nan Fung Life Sciences & 1 more	Novo Holdings & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Bolt Biotherapeutics's funding rounds and investors

The founders of Bolt Biotherapeutics is Edgar Engleman.

Here are the details of Bolt Biotherapeutics' key team members:

Edgar Engleman: Founder of Bolt Biotherapeutics.
Contact Info: 1 email address

View details of Bolt Biotherapeutics's Founder profiles and Board Members

Bolt Biotherapeutics' employee count trend

Bolt Biotherapeutics has 54 employees as of Mar 26. Here is Bolt Biotherapeutics's employee count trend over the years:

Employee count trend for Bolt Biotherapeutics

Uncover Bolt Biotherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bolt Biotherapeutics include Immuneel, Abcellera Biologics and Agios Pharmaceuticals. Here is the list of Top 10 competitors of Bolt Biotherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
2nd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
3rd	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
4th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	BlackRock, RA Capital Management & 9 others	70/100
5th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	69/100
6th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	68/100
7th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	67/100
8th	Immatics 2000, Tubingen (Germany), Public	Developer of T -cell-based immunotherapies for the treatment of cancer	$236M	Wellington Partners Venture Capital, Dievini ... & 18 others	67/100
9th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Deerfield & 5 others	66/100
10th	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	66/100
32nd	Bolt Biotherapeutics 2015, Redwood City (United States), Public	Developer of T-cell therapies for the treatment of cancer	$177M	Samsara BioCapital, Novo Holdings & 7 others	61/100